{
    "info": {
        "nct_id": "NCT03159676",
        "official_title": "Proton-Based Stereotactic Ablative Body Radiotherapy (SABR) for Select Patients With Clinically Localized Prostate Cancer.",
        "inclusion_criteria": "* Male, age ≥ 18 years.\n* Histological confirmation of adenocarcinoma of prostatic origin.\n* AJCC 7th edition clinical T1b-fdiabetes mellitus T2b.\n* AJCC clinical staging rules do not include findings from biopsy or imaging.\n* Gleason score ≤7 (International Society of Urological Pathologists grades 1-3).\n* Serum prostate-specific antigen ≤20 ng/mL.\n* Prostate-specific antigen <10 ng/mL, if dutasteride within last 90 days or finasteride within last 30 days.\n* Zubrod performance score 0-1.\n* Prostate volume <75-cc, determined by ultrasound, computed tomography or magnetic resonance imaging (modality with lesser volume is acceptable).\n* If neoadjuvant-concurrent androgen suppression is used, the prostate volume after the start of androgen suppression may be used.\n* American Urological Association voiding symptom index ≤15.\n* Ability to complete questionnaire(s) by themselves or with assistance.\n* Participation in a patient-reported outcomes survey program, inclusive of the Expanded Prostate Index Composite and CTCAE instruments.\n* Ability to provide informed written consent.\nMust be MALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Radiological- or pathologically-confirmed seminal vesicle invasion, lymph node involvement, or distant metastatic disease.\n\n  * Radiological- or biopsy-confirmed extraprostatic tumor extension without AJCC 7th edition clinical T3a classification remain eligible.\n* Prior or anticipated external radiotherapy or brachytherapy, transurethral resection of the prostate, prostatic cryoablation/focused ultrasound/laser therapy, prostatectomy, or prostatic enucleation.\n* Prior bilateral orchiectomy, planned long-term (>6 months duration) androgen suppression or peripheral androgen blockade, or chemotherapy or immunotherapy for prostate cancer.\n* Prior hemi- or total hip arthroplasty.\n* Diabetes mellitus associated with vascular ulcers or wound healing problems, ulcerative colitis, connective tissue disorder, or chronic (≥120 days) warfarin or clotting factor inhibitor (e.g., rivaroxaban) use planned.\n* Co-morbid severe concurrent disease which, in the judgment of the investigator, would result in life expectancy <5 years.\n\n  * Patients with a left cardiac ventricular assist device are ineligible.\n  * Patients with an implanted medical electronic device (e.g., cardiac pacemaker) remain eligible if device monitoring complies with standard of practice (e.g., Cardiology and Medical Physics evaluation, function checks and during-treatment monitoring).\n* Immunocompromised due to HIV positive state.\n* Medical or psychiatric conditions that preclude informed decision-making or adherence.\n* Prior registration to an Institutional Review Board-approved therapeutic research study that includes proton beam therapy or photon-based radiotherapy (e.g., randomization to proton beam therapy vs. photon-based radiotherapy).\n\n  * Registration to a non-therapeutic (e.g., biomarker, medical physics) only research study is not an exclusion.\n* Inability to start radiation per protocol.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Male, age ≥ 18 years.",
            "criterions": [
                {
                    "exact_snippets": "Male",
                    "criterion": "gender",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "male"
                        }
                    ]
                },
                {
                    "exact_snippets": "age ≥ 18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histological confirmation of adenocarcinoma of prostatic origin.",
            "criterions": [
                {
                    "exact_snippets": "Histological confirmation of adenocarcinoma of prostatic origin.",
                    "criterion": "adenocarcinoma of prostatic origin",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histological"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* AJCC 7th edition clinical T1b-fdiabetes mellitus T2b.",
            "criterions": [
                {
                    "exact_snippets": "AJCC 7th edition clinical T1b",
                    "criterion": "AJCC 7th edition clinical stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "T1b"
                        }
                    ]
                },
                {
                    "exact_snippets": "diabetes mellitus",
                    "criterion": "diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "T2b",
                    "criterion": "AJCC 7th edition clinical stage",
                    "requirements": [
                        {
                            "requirement_type": "stage",
                            "expected_value": "T2b"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* AJCC clinical staging rules do not include findings from biopsy or imaging.",
            "criterions": [
                {
                    "exact_snippets": "AJCC clinical staging rules do not include findings from biopsy",
                    "criterion": "AJCC clinical staging rules",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "AJCC clinical staging rules do not include findings from ... imaging",
                    "criterion": "AJCC clinical staging rules",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Gleason score ≤7 (International Society of Urological Pathologists grades 1-3).",
            "criterions": [
                {
                    "exact_snippets": "Gleason score ≤7",
                    "criterion": "Gleason score",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "N/A"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "International Society of Urological Pathologists grades 1-3",
                    "criterion": "International Society of Urological Pathologists grade",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 3,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum prostate-specific antigen ≤20 ng/mL.",
            "criterions": [
                {
                    "exact_snippets": "Serum prostate-specific antigen ≤20 ng/mL",
                    "criterion": "serum prostate-specific antigen",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": "<=",
                                "value": 20,
                                "unit": "ng/mL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prostate-specific antigen <10 ng/mL, if dutasteride within last 90 days or finasteride within last 30 days.",
            "criterions": [
                {
                    "exact_snippets": "Prostate-specific antigen <10 ng/mL",
                    "criterion": "prostate-specific antigen",
                    "requirements": [
                        {
                            "requirement_type": "level",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "ng/mL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "if dutasteride within last 90 days",
                    "criterion": "dutasteride usage",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "if ... finasteride within last 30 days",
                    "criterion": "finasteride usage",
                    "requirements": [
                        {
                            "requirement_type": "time since last use",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Zubrod performance score 0-1.",
            "criterions": [
                {
                    "exact_snippets": "Zubrod performance score 0-1",
                    "criterion": "Zubrod performance score",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prostate volume <75-cc, determined by ultrasound, computed tomography or magnetic resonance imaging (modality with lesser volume is acceptable).",
            "criterions": [
                {
                    "exact_snippets": "Prostate volume <75-cc",
                    "criterion": "prostate volume",
                    "requirements": [
                        {
                            "requirement_type": "size",
                            "expected_value": {
                                "operator": "<",
                                "value": 75,
                                "unit": "cc"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "determined by ultrasound, computed tomography or magnetic resonance imaging",
                    "criterion": "imaging modality",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "ultrasound",
                                "computed tomography",
                                "magnetic resonance imaging"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If neoadjuvant-concurrent androgen suppression is used, the prostate volume after the start of androgen suppression may be used.",
            "criterions": [
                {
                    "exact_snippets": "neoadjuvant-concurrent androgen suppression is used",
                    "criterion": "neoadjuvant-concurrent androgen suppression",
                    "requirements": [
                        {
                            "requirement_type": "usage",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "prostate volume after the start of androgen suppression may be used",
                    "criterion": "prostate volume",
                    "requirements": [
                        {
                            "requirement_type": "measurement timing",
                            "expected_value": "after the start of androgen suppression"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* American Urological Association voiding symptom index ≤15.",
            "criterions": [
                {
                    "exact_snippets": "American Urological Association voiding symptom index ≤15",
                    "criterion": "American Urological Association voiding symptom index",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 15,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to complete questionnaire(s) by themselves or with assistance.",
            "criterions": [
                {
                    "exact_snippets": "Ability to complete questionnaire(s) by themselves or with assistance.",
                    "criterion": "ability to complete questionnaire",
                    "requirements": [
                        {
                            "requirement_type": "assistance",
                            "expected_value": [
                                "by themselves",
                                "with assistance"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participation in a patient-reported outcomes survey program, inclusive of the Expanded Prostate Index Composite and CTCAE instruments.",
            "criterions": [
                {
                    "exact_snippets": "Participation in a patient-reported outcomes survey program",
                    "criterion": "participation in patient-reported outcomes survey program",
                    "requirements": [
                        {
                            "requirement_type": "participation",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "inclusive of the Expanded Prostate Index Composite",
                    "criterion": "Expanded Prostate Index Composite",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "inclusive of ... CTCAE instruments",
                    "criterion": "CTCAE instruments",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to provide informed written consent.",
            "criterions": [
                {
                    "exact_snippets": "Ability to provide informed written consent.",
                    "criterion": "informed written consent",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be MALE",
            "criterions": [
                {
                    "exact_snippets": "MALE",
                    "criterion": "gender",
                    "requirements": [
                        {
                            "requirement_type": "expected_value",
                            "expected_value": "male"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Radiological- or pathologically-confirmed seminal vesicle invasion, lymph node involvement, or distant metastatic disease.",
            "criterions": [
                {
                    "exact_snippets": "Radiological- or pathologically-confirmed seminal vesicle invasion",
                    "criterion": "seminal vesicle invasion",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": [
                                "radiological",
                                "pathological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Radiological- or pathologically-confirmed ... lymph node involvement",
                    "criterion": "lymph node involvement",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": [
                                "radiological",
                                "pathological"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Radiological- or pathologically-confirmed ... distant metastatic disease",
                    "criterion": "distant metastatic disease",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": [
                                "radiological",
                                "pathological"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Radiological- or biopsy-confirmed extraprostatic tumor extension without AJCC 7th edition clinical T3a classification remain eligible.",
            "criterions": [
                {
                    "exact_snippets": "Radiological- or biopsy-confirmed extraprostatic tumor extension",
                    "criterion": "extraprostatic tumor extension",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": [
                                "radiological",
                                "biopsy"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "without AJCC 7th edition clinical T3a classification",
                    "criterion": "AJCC 7th edition clinical T3a classification",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior or anticipated external radiotherapy or brachytherapy, transurethral resection of the prostate, prostatic cryoablation/focused ultrasound/laser therapy, prostatectomy, or prostatic enucleation.",
            "criterions": [
                {
                    "exact_snippets": "Prior or anticipated external radiotherapy",
                    "criterion": "external radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "prior or anticipated",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior or anticipated ... brachytherapy",
                    "criterion": "brachytherapy",
                    "requirements": [
                        {
                            "requirement_type": "prior or anticipated",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior or anticipated ... transurethral resection of the prostate",
                    "criterion": "transurethral resection of the prostate",
                    "requirements": [
                        {
                            "requirement_type": "prior or anticipated",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior or anticipated ... prostatic cryoablation/focused ultrasound/laser therapy",
                    "criterion": "prostatic cryoablation/focused ultrasound/laser therapy",
                    "requirements": [
                        {
                            "requirement_type": "prior or anticipated",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior or anticipated ... prostatectomy",
                    "criterion": "prostatectomy",
                    "requirements": [
                        {
                            "requirement_type": "prior or anticipated",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior or anticipated ... prostatic enucleation",
                    "criterion": "prostatic enucleation",
                    "requirements": [
                        {
                            "requirement_type": "prior or anticipated",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior bilateral orchiectomy, planned long-term (>6 months duration) androgen suppression or peripheral androgen blockade, or chemotherapy or immunotherapy for prostate cancer.",
            "criterions": [
                {
                    "exact_snippets": "Prior bilateral orchiectomy",
                    "criterion": "bilateral orchiectomy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "planned long-term (>6 months duration) androgen suppression",
                    "criterion": "androgen suppression",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "planned long-term (>6 months duration) ... peripheral androgen blockade",
                    "criterion": "peripheral androgen blockade",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "chemotherapy ... for prostate cancer",
                    "criterion": "chemotherapy for prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "planned",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "immunotherapy for prostate cancer",
                    "criterion": "immunotherapy for prostate cancer",
                    "requirements": [
                        {
                            "requirement_type": "planned",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior hemi- or total hip arthroplasty.",
            "criterions": [
                {
                    "exact_snippets": "Prior hemi- or total hip arthroplasty.",
                    "criterion": "hip arthroplasty",
                    "requirements": [
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "hemi",
                                "total"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diabetes mellitus associated with vascular ulcers or wound healing problems, ulcerative colitis, connective tissue disorder, or chronic (≥120 days) warfarin or clotting factor inhibitor (e.g., rivaroxaban) use planned.",
            "criterions": [
                {
                    "exact_snippets": "Diabetes mellitus associated with vascular ulcers or wound healing problems",
                    "criterion": "diabetes mellitus",
                    "requirements": [
                        {
                            "requirement_type": "association",
                            "expected_value": [
                                "vascular ulcers",
                                "wound healing problems"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "ulcerative colitis",
                    "criterion": "ulcerative colitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "connective tissue disorder",
                    "criterion": "connective tissue disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "chronic (≥120 days) warfarin or clotting factor inhibitor (e.g., rivaroxaban) use planned",
                    "criterion": "warfarin or clotting factor inhibitor use",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 120,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "planned",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Co-morbid severe concurrent disease which, in the judgment of the investigator, would result in life expectancy <5 years.",
            "criterions": [
                {
                    "exact_snippets": "Co-morbid severe concurrent disease",
                    "criterion": "co-morbid severe concurrent disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "life expectancy <5 years",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<",
                                "value": 5,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with a left cardiac ventricular assist device are ineligible.",
            "criterions": [
                {
                    "exact_snippets": "Patients with a left cardiac ventricular assist device are ineligible.",
                    "criterion": "left cardiac ventricular assist device",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with an implanted medical electronic device (e.g., cardiac pacemaker) remain eligible if device monitoring complies with standard of practice (e.g., Cardiology and Medical Physics evaluation, function checks and during-treatment monitoring).",
            "criterions": [
                {
                    "exact_snippets": "implanted medical electronic device (e.g., cardiac pacemaker)",
                    "criterion": "implanted medical electronic device",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "device monitoring complies with standard of practice",
                    "criterion": "device monitoring compliance",
                    "requirements": [
                        {
                            "requirement_type": "compliance",
                            "expected_value": "standard of practice"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Immunocompromised due to HIV positive state.",
            "criterions": [
                {
                    "exact_snippets": "Immunocompromised due to HIV positive state",
                    "criterion": "HIV status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Medical or psychiatric conditions that preclude informed decision-making or adherence.",
            "criterions": [
                {
                    "exact_snippets": "Medical or psychiatric conditions that preclude informed decision-making",
                    "criterion": "medical or psychiatric conditions",
                    "requirements": [
                        {
                            "requirement_type": "impact on decision-making",
                            "expected_value": "preclude informed decision-making"
                        }
                    ]
                },
                {
                    "exact_snippets": "Medical or psychiatric conditions that preclude ... adherence",
                    "criterion": "medical or psychiatric conditions",
                    "requirements": [
                        {
                            "requirement_type": "impact on adherence",
                            "expected_value": "preclude adherence"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior registration to an Institutional Review Board-approved therapeutic research study that includes proton beam therapy or photon-based radiotherapy (e.g., randomization to proton beam therapy vs. photon-based radiotherapy).",
            "criterions": [
                {
                    "exact_snippets": "Prior registration to an Institutional Review Board-approved therapeutic research study",
                    "criterion": "registration to an Institutional Review Board-approved therapeutic research study",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "includes proton beam therapy or photon-based radiotherapy",
                    "criterion": "therapeutic research study includes proton beam therapy or photon-based radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Registration to a non-therapeutic (e.g., biomarker, medical physics) only research study is not an exclusion.",
            "criterions": [
                {
                    "exact_snippets": "Registration to a non-therapeutic (e.g., biomarker, medical physics) only research study",
                    "criterion": "registration to a non-therapeutic research study",
                    "requirements": [
                        {
                            "requirement_type": "exclusion",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inability to start radiation per protocol.",
            "criterions": [
                {
                    "exact_snippets": "Inability to start radiation per protocol.",
                    "criterion": "ability to start radiation",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}